Canntab Therapeutics MMJ Files 11 Patent Applicati
Post# of 144491
(Total Views: 194)
Posted On: 05/04/2018 12:32:14 PM
Canntab Therapeutics MMJ Files 11 Patent Applications Related to Pharmaceutical #Cannabis.
Canntab's portfolio now includes 11 patent applications in the United States and internationally. These filings, which include 7 non-provisional US patent application and 4 PCT patent applications, build on Canntab's growing intellectual property portfolio, which already included 7 provisional US patent applications and 10 trademark applications in the United States and Canada. The patent applications that were filed pertain to a variety of Canntab's innovative technologies related to oral dosage formulations of pharmaceutical cannabis, including:
* Sustained Release Cannabinoid Formulations;
* Immediate Release Cannabidiol Formulations;
* Modified-Release Multi-Layer Cannabinoid Formulations;
* Flash-Melt Cannabinoid Formulations; and
* Bi-layer Cannabinoid Tablets.
These patent applications are part of Canntab's concerted strategy to develop a comprehensive intellectual property portfolio which covers the company's technology and formulations related to pharmaceutical preparations which contain natural or synthetic cannabinoids. Canntab is currently developing a number of products which utilize this technology, which includes a variety of extended released tablets containing a mixture of THC (Tetrahydrocannabinol) and CBD (Cannabidiol) that can be used to treat a number of ailments, such as
* sleep disorders;
* post-traumatic stress disorder (PTSD);
* social anxiety;
* addiction;
* arthritis;
* general pain; and
* the pain management and appetite loss associated with cancer treatments.
https://www.queenslandbauxite.com/
See QBL-board and website for latest UPDATES!
.Here you have the possibility to take advantage on facts and info from QBL.Like the QBL on ASX website chapter, who can provide verified facts; here is regulated on-line stockbrokers suggestion, no games info and a good sum up.Contact information to the QBL Investor service, who can reply on questions, serviceminded.
Canntab's portfolio now includes 11 patent applications in the United States and internationally. These filings, which include 7 non-provisional US patent application and 4 PCT patent applications, build on Canntab's growing intellectual property portfolio, which already included 7 provisional US patent applications and 10 trademark applications in the United States and Canada. The patent applications that were filed pertain to a variety of Canntab's innovative technologies related to oral dosage formulations of pharmaceutical cannabis, including:
* Sustained Release Cannabinoid Formulations;
* Immediate Release Cannabidiol Formulations;
* Modified-Release Multi-Layer Cannabinoid Formulations;
* Flash-Melt Cannabinoid Formulations; and
* Bi-layer Cannabinoid Tablets.
These patent applications are part of Canntab's concerted strategy to develop a comprehensive intellectual property portfolio which covers the company's technology and formulations related to pharmaceutical preparations which contain natural or synthetic cannabinoids. Canntab is currently developing a number of products which utilize this technology, which includes a variety of extended released tablets containing a mixture of THC (Tetrahydrocannabinol) and CBD (Cannabidiol) that can be used to treat a number of ailments, such as
* sleep disorders;
* post-traumatic stress disorder (PTSD);
* social anxiety;
* addiction;
* arthritis;
* general pain; and
* the pain management and appetite loss associated with cancer treatments.
https://www.queenslandbauxite.com/
See QBL-board and website for latest UPDATES!
.Here you have the possibility to take advantage on facts and info from QBL.Like the QBL on ASX website chapter, who can provide verified facts; here is regulated on-line stockbrokers suggestion, no games info and a good sum up.Contact information to the QBL Investor service, who can reply on questions, serviceminded.
(0)
(0)
Robert
Scroll down for more posts ▼